Medium impact
08.02.19a, Mirikizumab-mrkz (Omvoh®) for Intravenous Use
Independence Blue Cross·Effective Dec 29, 2025
HCPCS J7571 is referenced in 1 tracked payer policy change from Independence Blue Cross. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J7571 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.